Polaryx Therapeutics, Inc.
PLYX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002075320
No open-market purchases or sales by Polaryx Therapeutics, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $5.83M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Polaryx Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- −1 vs. Q1 2026
- Shares held
- 2.19M
- −74.0K (−3.3%) vs. Q1 2026
- Total value
- $5.83M
- −$11.3M (−66.0%) vs. Q1 2026
- New holders
- 4
- 3 more added
- Sold out
- 5
- 2 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PLYX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $5.83M |
| Q1 2026 | 14 | $17.1M |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Polaryx Therapeutics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 1,657,872 | $4.41M | 0.00% | −5160.0% | Reduced |
| Geode Capital Management, LLC | 170,998 | $455.1K | 0.00% | +325+0.2% | Added |
| Vanguard Fiduciary Trust Co | 105,072 | $279.5K | 0.00% | +516+0.5% | Added |
| HRT Financial LP | 82,094 | $218.0K | 0.00% | +82,094 | New |
| State Street Corp | 58,104 | $154.6K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 41,012 | $109.1K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 31,441 | $83.6K | 0.00% | +31,441 | New |
| Northern Trust Corp | 27,987 | $74.4K | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 7,727 | $20.6K | 0.00% | +7,727 | New |
| Vanguard Global Advisers, LLC | 6,318 | $16.8K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,002 | $7.99K | 0.00% | +1,221+68.6% | Added |
| UBS Group AG | 1,283 | $3.41K | 0.00% | −12,196−90.5% | Reduced |
| Fortitude Family Office, LLC | 189 | $503 | 0.00% | +189 | New |
| Millennium Management LLC | 0 | $0 | 0.00% | −127,525−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −25,881−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −13,483−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −12,406−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −5,543−100.0% | Sold out |